| | |
Percent (95%CI) with symptoms (treated minus placebo)†
|
|---|
|
Drug class
|
No. of trials
|
1/2 standard dose
|
Standard dose
|
Twice standard dose
|
|---|
|
Thiazides
|
59
|
2.0 [-2.2 to 6.3]
|
9.9 [6.6 to 13.2]
|
17.8 [11.5 to 24.2]
|
|
BBs
|
62
|
5.5 [0.3 to 10.7]
|
7.5 [4.0 to 10.9]
|
9.4 [3.6 to 15.2]
|
|
ACEi
|
96
|
3.9 [-3.7 to 11.6]
|
3.9 [-0.5 to 8.3]
|
3.9 [-0.2 to 8.0]
|
|
ARBs
|
44
|
-1.8 [-10.2 to 6.5]
|
0 [-5.4 to 5.4]
|
1.9 [-5.6 to 9.3]
|
|
CCBs
|
96
|
1.6 [-3.5 to 6.7]
|
8.3 [4.8 to 11.8]
|
14.9 [9.8 to 20.1]
|
- ACE = angiotensin converting enzyme. *Calculated as difference between treated and placebo groups in proportion of participants who developed one or more symptoms, excluding headaches, which were significantly less common in people receiving treatment. †Commonest symptoms: thiazides–dizziness, impotence, nausea, muscle cramp; Beta-blockers–cold extremities, fatigue, nausea; ACE inhibitors–cough; calcium channel blockers–flushing, ankle oedema, dizziness.
